Aurobindo
Aurobindo Pharma's debt pain recedes after calling off deal with Sandoz
Aurobindo was scheduled to acquire the portfolio with an upfront purchase price of $900 million in cash
 "Aurobindo Pharma's debt pain recedes after calling off deal with Sandoz")
Aurobindo terminates $900-million Sandoz product acquistion deal
A mutual decision to cancel the agreement was taken as approval from US Federal Trade Commission was not obtained within anticipated timelines
 "Aurobindo terminates $900-million Sandoz product acquistion deal")
Regulatory overhang may dent Aurobindo Pharma earnings estimate by 15-20%
The stock tanked to its five-year low before closing 8.7 per cent lower on Thursday
 "Regulatory overhang may dent Aurobindo Pharma earnings estimate by 15-20%")
Aurobindo Pharma rises 3% after firm's clarification on FDA observations
The exchange had sought a clarification from the company regarding declining share prices on the back of USFDA observations
Aurobindo faces US suit over carcinogenic elements in blood pressure drug
Aurobindo scrip lost as much as Rs 22 (down close to 3%) on Tuesday after touching a new 52-week high of Rs 830
 "Aurobindo faces US suit over carcinogenic elements in blood pressure drug")
Higher volumes, launches help Aurobindo beat peers
Strong US product pipeline to help sustain the performance
 "Higher volumes, launches help Aurobindo beat peers")
Concerns overdone on Aurobindo Pharma
The Pharma major sheds nearly 10% since the start of the month on regulatory issues
 "Concerns overdone on Aurobindo Pharma")
Aurobindo: US sales propelling growth
US business growth is expected to remain robust and help earnings grow 18% annually till FY19
